IN2013MU02145A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02145A
IN2013MU02145A IN2145MU2013A IN2013MU02145A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A IN 2145MU2013 A IN2145MU2013 A IN 2145MU2013A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A
Authority
IN
India
Prior art keywords
monoclonal antibody
purification
provides
desired monoclonal
purity
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Sanjeev Kumar Mendiratta
Avanish Kumar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU02145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to TW103121726A priority Critical patent/TWI596107B/zh
Priority to ARP140102380A priority patent/AR096713A1/es
Priority to US14/895,432 priority patent/US9708365B2/en
Priority to EP14777867.4A priority patent/EP3013849B1/en
Priority to CN201480031532.XA priority patent/CN105263947A/zh
Priority to CA2911874A priority patent/CA2911874A1/en
Priority to BR112015031196A priority patent/BR112015031196A2/pt
Priority to KR1020157035759A priority patent/KR101683415B1/ko
Priority to AU2014300486A priority patent/AU2014300486B2/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2145MU2013 priority patent/IN2013MU02145A/en
Priority to PCT/IN2014/000421 priority patent/WO2014207763A1/en
Priority to SG11201509502XA priority patent/SG11201509502XA/en
Priority to NZ714079A priority patent/NZ714079A/en
Priority to JP2015563045A priority patent/JP6039828B2/ja
Priority to HK16105366.7A priority patent/HK1217344A1/zh
Priority to EA201592192A priority patent/EA201592192A1/ru
Priority to MX2015016586A priority patent/MX350610B/es
Publication of IN2013MU02145A publication Critical patent/IN2013MU02145A/en
Priority to ZA2015/08258A priority patent/ZA201508258B/en
Priority to IL242649A priority patent/IL242649A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
IN2145MU2013 2013-06-25 2014-06-25 IN2013MU02145A (enExample)

Priority Applications (19)

Application Number Priority Date Filing Date Title
TW103121726A TWI596107B (zh) 2013-06-25 2014-06-24 單株抗體之新穎純化方法
ARP140102380A AR096713A1 (es) 2013-06-25 2014-06-24 Proceso de purificación para anticuerpos monoclonales
MX2015016586A MX350610B (es) 2013-06-25 2014-06-25 Proceso para la purificacion de anticuerpos monoclonales.
PCT/IN2014/000421 WO2014207763A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
CN201480031532.XA CN105263947A (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工艺
CA2911874A CA2911874A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
BR112015031196A BR112015031196A2 (pt) 2013-06-25 2014-06-25 “processo de purificação de anticorpo monoclonal”
KR1020157035759A KR101683415B1 (ko) 2013-06-25 2014-06-25 단일클론항체에 대한 정제 방법
AU2014300486A AU2014300486B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
US14/895,432 US9708365B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
IN2145MU2013 IN2013MU02145A (enExample) 2013-06-25 2014-06-25
EP14777867.4A EP3013849B1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
SG11201509502XA SG11201509502XA (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
NZ714079A NZ714079A (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
JP2015563045A JP6039828B2 (ja) 2013-06-25 2014-06-25 モノクローナル抗体の精製方法
HK16105366.7A HK1217344A1 (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工序
EA201592192A EA201592192A1 (ru) 2013-06-25 2014-06-25 Способ очистки моноклональных антител
ZA2015/08258A ZA201508258B (en) 2013-06-25 2015-11-09 Purification process for monoclonal antibodies
IL242649A IL242649A (en) 2013-06-25 2015-11-18 Purification process of monoclonal antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2145MU2013 IN2013MU02145A (enExample) 2013-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
IN2013MU02145A true IN2013MU02145A (enExample) 2015-06-05

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2145MU2013 IN2013MU02145A (enExample) 2013-06-25 2014-06-25

Country Status (19)

Country Link
US (1) US9708365B2 (enExample)
EP (1) EP3013849B1 (enExample)
JP (1) JP6039828B2 (enExample)
KR (1) KR101683415B1 (enExample)
CN (1) CN105263947A (enExample)
AR (1) AR096713A1 (enExample)
AU (1) AU2014300486B2 (enExample)
BR (1) BR112015031196A2 (enExample)
CA (1) CA2911874A1 (enExample)
EA (1) EA201592192A1 (enExample)
HK (1) HK1217344A1 (enExample)
IL (1) IL242649A (enExample)
IN (1) IN2013MU02145A (enExample)
MX (1) MX350610B (enExample)
NZ (1) NZ714079A (enExample)
SG (1) SG11201509502XA (enExample)
TW (1) TWI596107B (enExample)
WO (1) WO2014207763A1 (enExample)
ZA (1) ZA201508258B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH088818Y2 (ja) 1989-12-21 1996-03-13 株式会社イナックス タイル用捺印装置
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3268100A1 (en) 2015-03-13 2018-01-17 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
JP7073253B2 (ja) 2015-08-21 2022-05-23 エフ．ホフマン－ラ ロシュ アーゲー アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
ES2877532T3 (es) * 2015-08-21 2021-11-17 Hoffmann La Roche Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad
WO2017032610A1 (en) * 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Affinity chromatography purification with low conductivity wash buffer
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
KR20230041834A (ko) 2016-08-16 2023-03-24 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
CN119492842A (zh) 2016-10-25 2025-02-21 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
EP3532046A4 (en) 2016-10-28 2020-12-30 Merck Sharp & Dohme Corp. A PURIFICATION PROCESS FOR REMOVING VARIANTS OF TYROSINE SULPHATION ANTIBODIES; PURIFIED COMPOSITIONS
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
GEAP202315128A (en) 2016-12-23 2023-02-10 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
TWI679052B (zh) * 2017-05-16 2019-12-11 南韓商Ｃｊ醫藥健康股份有限公司 使用親和力層析術純化抗體或其抗體片段的方法
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
CN118416215A (zh) 2017-09-19 2024-08-02 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
EP3774881A1 (en) * 2018-04-02 2021-02-17 Amgen Inc. Erenumab compositions and uses thereof
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3823594B1 (en) * 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
CN111269316B (zh) * 2018-12-04 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗her2单克隆抗体的纯化方法
SG11202107192VA (en) * 2019-01-23 2021-07-29 Daiichi Sankyo Co Ltd Methods for purifying antibodies comprising of a process by using activated carbon materials
EP3934620A1 (en) 2019-03-05 2022-01-12 Regeneron Pharmaceuticals, Inc. Human serum albumin in formulations
EP4061825A1 (en) * 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography
WO2021139720A1 (zh) * 2020-01-08 2021-07-15 信达生物制药(苏州)有限公司 阿达木单抗纯化方法及其稳定组合物
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (en) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Protein purification by affinity chromatography
US12454567B2 (en) 2021-07-27 2025-10-28 Ariel Scientific Innovations Ltd. Large scale purification of antibodies
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (en) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Resin and chromatography column that purifies antibodies with protease resistant small peptides
CN118725127B (zh) * 2024-07-11 2025-11-28 信立泰(苏州)药业有限公司 一种抗pcsk9单克隆抗体的分离纯化方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1308455B9 (en) 1998-05-06 2006-06-14 Genentech, Inc. A composition comprising anti-HER2 antibodies
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1084136B1 (en) * 1998-06-01 2004-08-25 Genentech, Inc. Separation of antibody monomers from its multimers by use of ion-exchange chromatography
JPWO2004087761A1 (ja) 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
DK1869065T3 (da) 2005-03-11 2020-06-08 Wyeth Llc Fremgangsmåde til kromatografi med svag opdeling
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
AR062711A1 (es) 2006-09-08 2008-11-26 Wyeth Corp Lavado de arginina en l a purificacion de proteinas usando cromatografia de afinidad
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
US20110166332A1 (en) 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
KR101753569B1 (ko) 2010-01-22 2017-07-04 베링거 인겔하임 인터내셔날 게엠베하 Ｆｃ―함유 단백질을 정제하는 크로마토그래피 방법
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
SG10201508401TA (en) * 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
JP2013544524A (ja) * 2010-12-06 2013-12-19 ターポン バイオシステムズ，インコーポレイテッド 生物学的生成物の連続プロセス法
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
WO2013066707A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Chromatography process for resolving heterogeneous antibody aggregates
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
AU2014240596B2 (en) * 2013-03-14 2018-09-27 Amgen Inc. Removal of leaked affinity purification ligand
CN105324393A (zh) * 2013-05-13 2016-02-10 米迪缪尼有限公司 具有最小单体分离的重组多克隆抗体多聚体的分离
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法

Also Published As

Publication number Publication date
TW201512217A (zh) 2015-04-01
EP3013849B1 (en) 2017-09-13
TWI596107B (zh) 2017-08-21
CA2911874A1 (en) 2014-12-31
IL242649A (en) 2016-03-31
US20160115195A1 (en) 2016-04-28
HK1217344A1 (zh) 2017-01-06
MX350610B (es) 2017-09-11
JP6039828B2 (ja) 2016-12-07
WO2014207763A1 (en) 2014-12-31
KR101683415B1 (ko) 2016-12-06
AR096713A1 (es) 2016-01-27
EA201592192A1 (ru) 2016-07-29
MX2015016586A (es) 2016-03-16
SG11201509502XA (en) 2015-12-30
CN105263947A (zh) 2016-01-20
NZ714079A (en) 2017-05-26
US9708365B2 (en) 2017-07-18
KR20160003311A (ko) 2016-01-08
JP2016525500A (ja) 2016-08-25
BR112015031196A2 (pt) 2017-07-25
AU2014300486B2 (en) 2016-06-30
EP3013849A1 (en) 2016-05-04
ZA201508258B (en) 2017-03-29
AU2014300486A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
NZ714079A (en) Purification process for monoclonal antibodies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2015015482A (es) Proceso continuo de multiples etapas para purificar anticuerpos.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
HK1206755A1 (en) Low acidic species compositions and methods for producing and using the same
PH12022551228A1 (en) Trem2 antibodies and uses thereof
WO2019083318A3 (ko) 개선된 면역글로불린의 정제방법
MX2019008996A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EP3560956A3 (en) Methods of treating inflammatory diseases
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
MX368107B (es) Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
SG10201806643WA (en) Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
SG11201802997WA (en) Affinity chromatography carrier and method for purifying biological substance
MY197993A (en) Method for protein purification
MX2018015873A (es) Preparacion de derivados del factor xa.
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
MX2017013454A (es) Deteccion de moleculas de acido nucleico.
EP4239329A3 (en) Method and apparatus
HK1216654A1 (zh) 使用離子交換色譜來控制高甘露糖糖型的水平的方法